Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma

Hao Liu, Kamila Naxerova, Matthias Pinter, Joao Incio, Hang Lee, Kohei Shigeta, William W. Ho, Jonathan A. Crain, Alex Jacobson, Theodoros Michelakos, Daniella Dias-Santos, Andrea Zanconato, Theodore S. Hong, Jeffrey W. Clark, Janet E. Murphy, David P. Ryan, Vikram Deshpande, Keith D. Lillemoe, Carlos Fernandez del Castillo, Michael DownesRonald M. Evans, James Michaelson, Cristina R. Ferrone, Yves Boucher, Rakesh K. Jain

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Angiotensin system inhibitors (ASI) can improve score–adjusted analysis also showed a longer median OS for prognosis in multiple cancer types, including pancreatic ductal chronic ASI users. In unresected patients, the beneficial effect of adenocarcinoma (PDAC). However, no study has examined the ASIs was significant in patients with locally advanced disease, but effect of ASIs alone or combined with adjuvant chemotherapy in not in metastatic patients. RNA-Seq analysis revealed in tumors of resected PDAC patients. ASI users (lisinopril) a normalized extracellular matrix, a reduced Experimental Design: We performed an analysis of the records expression of genes involved in PDAC progression (e.g., WNT of ASI users and nonuser patients with PDAC seen at Massachusetts and Notch signaling), and an increased expression of genes linked General Hospital (Boston, MA) between January 2006 and Decem-with the activity of T cells and antigen-presenting cells. Finally, ber 2010. To identify mechanisms of ASIs in PDAC, we performed chronic use of ASI was associated with a gene expression signature RNA sequencing (RNA-Seq) of resected primary lesions. that is predictive of survival in independent validation cohorts. Results: A total of 794 consecutive patients were included. In Conclusions: In patients with nonmetastatic PDAC, chronic ASI 299 resected patients, ASI users experienced longer overall survival use is associated with longer OS independently of chemotherapy. (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P ¼ Our RNA-Seq analysis suggests that ASIs reduce the malignant 0.011) and adjusted multivariate [HR, 0.505; 95% confidence potential of cancer cells and stimulate the immune microenviron-interval (CI), 0.339–0.750; P ¼ 0.001] analyses.

Original languageEnglish
Pages (from-to)5959-5969
Number of pages11
JournalClinical Cancer Research
Volume23
Issue number19
DOIs
Publication statusPublished - 2017 Oct 1
Externally publishedYes

Fingerprint

Angiotensins
Adenocarcinoma
Survival
RNA Sequence Analysis
Lisinopril
Gene Expression
Viral Tumor Antigens
Antigen-Presenting Cells
Adjuvant Chemotherapy
Pancreatic Neoplasms
Transcriptome
General Hospitals
Extracellular Matrix
Neoplasms
Research Design
T-Lymphocytes
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma. / Liu, Hao; Naxerova, Kamila; Pinter, Matthias; Incio, Joao; Lee, Hang; Shigeta, Kohei; Ho, William W.; Crain, Jonathan A.; Jacobson, Alex; Michelakos, Theodoros; Dias-Santos, Daniella; Zanconato, Andrea; Hong, Theodore S.; Clark, Jeffrey W.; Murphy, Janet E.; Ryan, David P.; Deshpande, Vikram; Lillemoe, Keith D.; Castillo, Carlos Fernandez del; Downes, Michael; Evans, Ronald M.; Michaelson, James; Ferrone, Cristina R.; Boucher, Yves; Jain, Rakesh K.

In: Clinical Cancer Research, Vol. 23, No. 19, 01.10.2017, p. 5959-5969.

Research output: Contribution to journalArticle

Liu, H, Naxerova, K, Pinter, M, Incio, J, Lee, H, Shigeta, K, Ho, WW, Crain, JA, Jacobson, A, Michelakos, T, Dias-Santos, D, Zanconato, A, Hong, TS, Clark, JW, Murphy, JE, Ryan, DP, Deshpande, V, Lillemoe, KD, Castillo, CFD, Downes, M, Evans, RM, Michaelson, J, Ferrone, CR, Boucher, Y & Jain, RK 2017, 'Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma', Clinical Cancer Research, vol. 23, no. 19, pp. 5959-5969. https://doi.org/10.1158/1078-0432.CCR-17-0256
Liu, Hao ; Naxerova, Kamila ; Pinter, Matthias ; Incio, Joao ; Lee, Hang ; Shigeta, Kohei ; Ho, William W. ; Crain, Jonathan A. ; Jacobson, Alex ; Michelakos, Theodoros ; Dias-Santos, Daniella ; Zanconato, Andrea ; Hong, Theodore S. ; Clark, Jeffrey W. ; Murphy, Janet E. ; Ryan, David P. ; Deshpande, Vikram ; Lillemoe, Keith D. ; Castillo, Carlos Fernandez del ; Downes, Michael ; Evans, Ronald M. ; Michaelson, James ; Ferrone, Cristina R. ; Boucher, Yves ; Jain, Rakesh K. / Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 19. pp. 5959-5969.
@article{cf0fb39a33ff4624862b5b096c5e0785,
title = "Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma",
abstract = "Purpose: Angiotensin system inhibitors (ASI) can improve score–adjusted analysis also showed a longer median OS for prognosis in multiple cancer types, including pancreatic ductal chronic ASI users. In unresected patients, the beneficial effect of adenocarcinoma (PDAC). However, no study has examined the ASIs was significant in patients with locally advanced disease, but effect of ASIs alone or combined with adjuvant chemotherapy in not in metastatic patients. RNA-Seq analysis revealed in tumors of resected PDAC patients. ASI users (lisinopril) a normalized extracellular matrix, a reduced Experimental Design: We performed an analysis of the records expression of genes involved in PDAC progression (e.g., WNT of ASI users and nonuser patients with PDAC seen at Massachusetts and Notch signaling), and an increased expression of genes linked General Hospital (Boston, MA) between January 2006 and Decem-with the activity of T cells and antigen-presenting cells. Finally, ber 2010. To identify mechanisms of ASIs in PDAC, we performed chronic use of ASI was associated with a gene expression signature RNA sequencing (RNA-Seq) of resected primary lesions. that is predictive of survival in independent validation cohorts. Results: A total of 794 consecutive patients were included. In Conclusions: In patients with nonmetastatic PDAC, chronic ASI 299 resected patients, ASI users experienced longer overall survival use is associated with longer OS independently of chemotherapy. (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P ¼ Our RNA-Seq analysis suggests that ASIs reduce the malignant 0.011) and adjusted multivariate [HR, 0.505; 95{\%} confidence potential of cancer cells and stimulate the immune microenviron-interval (CI), 0.339–0.750; P ¼ 0.001] analyses.",
author = "Hao Liu and Kamila Naxerova and Matthias Pinter and Joao Incio and Hang Lee and Kohei Shigeta and Ho, {William W.} and Crain, {Jonathan A.} and Alex Jacobson and Theodoros Michelakos and Daniella Dias-Santos and Andrea Zanconato and Hong, {Theodore S.} and Clark, {Jeffrey W.} and Murphy, {Janet E.} and Ryan, {David P.} and Vikram Deshpande and Lillemoe, {Keith D.} and Castillo, {Carlos Fernandez del} and Michael Downes and Evans, {Ronald M.} and James Michaelson and Ferrone, {Cristina R.} and Yves Boucher and Jain, {Rakesh K.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-17-0256",
language = "English",
volume = "23",
pages = "5959--5969",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma

AU - Liu, Hao

AU - Naxerova, Kamila

AU - Pinter, Matthias

AU - Incio, Joao

AU - Lee, Hang

AU - Shigeta, Kohei

AU - Ho, William W.

AU - Crain, Jonathan A.

AU - Jacobson, Alex

AU - Michelakos, Theodoros

AU - Dias-Santos, Daniella

AU - Zanconato, Andrea

AU - Hong, Theodore S.

AU - Clark, Jeffrey W.

AU - Murphy, Janet E.

AU - Ryan, David P.

AU - Deshpande, Vikram

AU - Lillemoe, Keith D.

AU - Castillo, Carlos Fernandez del

AU - Downes, Michael

AU - Evans, Ronald M.

AU - Michaelson, James

AU - Ferrone, Cristina R.

AU - Boucher, Yves

AU - Jain, Rakesh K.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: Angiotensin system inhibitors (ASI) can improve score–adjusted analysis also showed a longer median OS for prognosis in multiple cancer types, including pancreatic ductal chronic ASI users. In unresected patients, the beneficial effect of adenocarcinoma (PDAC). However, no study has examined the ASIs was significant in patients with locally advanced disease, but effect of ASIs alone or combined with adjuvant chemotherapy in not in metastatic patients. RNA-Seq analysis revealed in tumors of resected PDAC patients. ASI users (lisinopril) a normalized extracellular matrix, a reduced Experimental Design: We performed an analysis of the records expression of genes involved in PDAC progression (e.g., WNT of ASI users and nonuser patients with PDAC seen at Massachusetts and Notch signaling), and an increased expression of genes linked General Hospital (Boston, MA) between January 2006 and Decem-with the activity of T cells and antigen-presenting cells. Finally, ber 2010. To identify mechanisms of ASIs in PDAC, we performed chronic use of ASI was associated with a gene expression signature RNA sequencing (RNA-Seq) of resected primary lesions. that is predictive of survival in independent validation cohorts. Results: A total of 794 consecutive patients were included. In Conclusions: In patients with nonmetastatic PDAC, chronic ASI 299 resected patients, ASI users experienced longer overall survival use is associated with longer OS independently of chemotherapy. (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P ¼ Our RNA-Seq analysis suggests that ASIs reduce the malignant 0.011) and adjusted multivariate [HR, 0.505; 95% confidence potential of cancer cells and stimulate the immune microenviron-interval (CI), 0.339–0.750; P ¼ 0.001] analyses.

AB - Purpose: Angiotensin system inhibitors (ASI) can improve score–adjusted analysis also showed a longer median OS for prognosis in multiple cancer types, including pancreatic ductal chronic ASI users. In unresected patients, the beneficial effect of adenocarcinoma (PDAC). However, no study has examined the ASIs was significant in patients with locally advanced disease, but effect of ASIs alone or combined with adjuvant chemotherapy in not in metastatic patients. RNA-Seq analysis revealed in tumors of resected PDAC patients. ASI users (lisinopril) a normalized extracellular matrix, a reduced Experimental Design: We performed an analysis of the records expression of genes involved in PDAC progression (e.g., WNT of ASI users and nonuser patients with PDAC seen at Massachusetts and Notch signaling), and an increased expression of genes linked General Hospital (Boston, MA) between January 2006 and Decem-with the activity of T cells and antigen-presenting cells. Finally, ber 2010. To identify mechanisms of ASIs in PDAC, we performed chronic use of ASI was associated with a gene expression signature RNA sequencing (RNA-Seq) of resected primary lesions. that is predictive of survival in independent validation cohorts. Results: A total of 794 consecutive patients were included. In Conclusions: In patients with nonmetastatic PDAC, chronic ASI 299 resected patients, ASI users experienced longer overall survival use is associated with longer OS independently of chemotherapy. (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P ¼ Our RNA-Seq analysis suggests that ASIs reduce the malignant 0.011) and adjusted multivariate [HR, 0.505; 95% confidence potential of cancer cells and stimulate the immune microenviron-interval (CI), 0.339–0.750; P ¼ 0.001] analyses.

UR - http://www.scopus.com/inward/record.url?scp=85030537609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030537609&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0256

DO - 10.1158/1078-0432.CCR-17-0256

M3 - Article

C2 - 28600474

AN - SCOPUS:85030537609

VL - 23

SP - 5959

EP - 5969

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -